Publications by authors named "M Praga"
The treatment landscape for IgA nephropathy (IgAN) is rapidly evolving with the introduction of novel therapies targeting diverse disease pathways. Some have already been approved in different countries, while others are under investigation in randomized controlled trials (RCTs) with encouraging results. However, almost all performed RCTs have included only patients with refractory non-nephrotic proteinuria and preserved renal function.
View Article and Find Full Text PDFArticle Synopsis
- The haemolytic uraemic syndromes (HUS) include various conditions, with some linked to complement activation (CaHUS).
- The 2023 International Society of Nephrology HUS Forum featured experts discussing the latest knowledge, uncertainties, and proposed solutions in diagnosing and managing HUS.
- Key areas needing research include naming conventions, complement testing, identifying biomarkers, genetic factors for aHUS, treatment strategies for C5 inhibitors, and improving access to care for patients.
Article Synopsis
- * Despite these positive outcomes, the effectiveness of SGLT2i in treating patients with glomerulonephritis remains uncertain due to various study limitations.
- * This manuscript reviews evidence for the use of SGLT2i in glomerular diseases and discusses both the limitations and their potential clinical role.
Background: Primary membranous nephropathy (PMN) is usually caused by anti-phospholipase A2 receptor (PLA2R) autoantibodies. There are different therapeutic options according to baseline risk. Novel biomarkers are needed to optimize risk stratification and predict and monitor the response to therapy, as proteinuria responses may be delayed.
View Article and Find Full Text PDF